<?xml version="1.0" encoding="UTF-8"?>
<gtr:projectOverview xmlns:gtr="http://gtr.ukri.org/api"><gtr:projectComposition><gtr:collaborations><gtr:collaborator url="http://gtr.ukri.org:80/organisation/9E6E29A1-FFE3-487C-84F6-02CD1B6E313A"><gtr:id>9E6E29A1-FFE3-487C-84F6-02CD1B6E313A</gtr:id><gtr:name>National Institute for Biological Standards and Control (NIBSC)</gtr:name></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/31BAAEA1-1BCB-4D42-B1B3-4FC2539E6F43"><gtr:id>31BAAEA1-1BCB-4D42-B1B3-4FC2539E6F43</gtr:id><gtr:name>Public Health England</gtr:name><gtr:address><gtr:line1>Porton Down</gtr:line1><gtr:line4>Salisbury</gtr:line4><gtr:line5>Wiltshire</gtr:line5><gtr:postCode>SP4 0JG</gtr:postCode><gtr:region>South West</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/453DB5AB-8BFE-4E0A-B761-1C39BD880D5D"><gtr:id>453DB5AB-8BFE-4E0A-B761-1C39BD880D5D</gtr:id><gtr:name>Scripps Research Institute</gtr:name></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/D1367D45-734D-4891-9671-3C7C7C31D0A0"><gtr:id>D1367D45-734D-4891-9671-3C7C7C31D0A0</gtr:id><gtr:name>UCB Pharma</gtr:name><gtr:address><gtr:line1>Researchdreef 60</gtr:line1><gtr:line2>Allee de la Recherche 60</gtr:line2><gtr:postCode>B-1070</gtr:postCode><gtr:region>Outside UK</gtr:region><gtr:country>Belgium</gtr:country></gtr:address></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/BC911109-1671-4D57-BF27-8F8A86FF2D10"><gtr:id>BC911109-1671-4D57-BF27-8F8A86FF2D10</gtr:id><gtr:name>HUMABs Biomed, Bellinzona,Switzerland</gtr:name></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/4C6CADA1-1825-4102-82B3-3E25082120D5"><gtr:id>4C6CADA1-1825-4102-82B3-3E25082120D5</gtr:id><gtr:name>EBOVAC2 Consortium</gtr:name></gtr:collaborator></gtr:collaborations><gtr:leadResearchOrganisation url="http://gtr.ukri.org:80/organisation/31AF7C42-D7C4-47FF-A5D8-19AADBAD30A9"><gtr:id>31AF7C42-D7C4-47FF-A5D8-19AADBAD30A9</gtr:id><gtr:name>MRC Human Immunology Unit</gtr:name><gtr:address><gtr:line1>Weatherall Inst of Molecular Medicine</gtr:line1><gtr:line2>John Radcliffe Hospital</gtr:line2><gtr:line3>Headington</gtr:line3><gtr:line4>Oxford</gtr:line4><gtr:postCode>OX1 9DS</gtr:postCode><gtr:region>South East</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:typeInd>RO</gtr:typeInd></gtr:leadResearchOrganisation><gtr:organisationRoles><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/31AF7C42-D7C4-47FF-A5D8-19AADBAD30A9"><gtr:id>31AF7C42-D7C4-47FF-A5D8-19AADBAD30A9</gtr:id><gtr:name>MRC Human Immunology Unit</gtr:name><gtr:address><gtr:line1>Weatherall Inst of Molecular Medicine</gtr:line1><gtr:line2>John Radcliffe Hospital</gtr:line2><gtr:line3>Headington</gtr:line3><gtr:line4>Oxford</gtr:line4><gtr:postCode>OX1 9DS</gtr:postCode><gtr:region>South East</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>LEAD_RO</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/9E6E29A1-FFE3-487C-84F6-02CD1B6E313A"><gtr:id>9E6E29A1-FFE3-487C-84F6-02CD1B6E313A</gtr:id><gtr:name>National Institute for Biological Standards and Control (NIBSC)</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/31BAAEA1-1BCB-4D42-B1B3-4FC2539E6F43"><gtr:id>31BAAEA1-1BCB-4D42-B1B3-4FC2539E6F43</gtr:id><gtr:name>Public Health England</gtr:name><gtr:address><gtr:line1>Porton Down</gtr:line1><gtr:line4>Salisbury</gtr:line4><gtr:line5>Wiltshire</gtr:line5><gtr:postCode>SP4 0JG</gtr:postCode><gtr:region>South West</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/453DB5AB-8BFE-4E0A-B761-1C39BD880D5D"><gtr:id>453DB5AB-8BFE-4E0A-B761-1C39BD880D5D</gtr:id><gtr:name>Scripps Research Institute</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/D1367D45-734D-4891-9671-3C7C7C31D0A0"><gtr:id>D1367D45-734D-4891-9671-3C7C7C31D0A0</gtr:id><gtr:name>UCB Pharma</gtr:name><gtr:address><gtr:line1>Researchdreef 60</gtr:line1><gtr:line2>Allee de la Recherche 60</gtr:line2><gtr:postCode>B-1070</gtr:postCode><gtr:region>Outside UK</gtr:region><gtr:country>Belgium</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/BC911109-1671-4D57-BF27-8F8A86FF2D10"><gtr:id>BC911109-1671-4D57-BF27-8F8A86FF2D10</gtr:id><gtr:name>HUMABs Biomed, Bellinzona,Switzerland</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/4C6CADA1-1825-4102-82B3-3E25082120D5"><gtr:id>4C6CADA1-1825-4102-82B3-3E25082120D5</gtr:id><gtr:name>EBOVAC2 Consortium</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole></gtr:organisationRoles><gtr:personRoles><gtr:personRole url="http://gtr.ukri.org:80/person/42EE47A1-8247-4CCB-B7D5-99FD2758D80B"><gtr:id>42EE47A1-8247-4CCB-B7D5-99FD2758D80B</gtr:id><gtr:firstName>Vincenzo</gtr:firstName><gtr:surname>Cerundolo</gtr:surname><gtr:roles><gtr:role><gtr:name>PRINCIPAL_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole></gtr:personRoles><gtr:project url="http://gtr.ukri.org:80/projects?ref=MC_PC_15002"><gtr:id>7EFD22AE-AA11-41A7-A1EA-4B5D061259F2</gtr:id><gtr:title>MRC and DfID contribution to jointly funded rapid response strategic award</gtr:title><gtr:status>Closed</gtr:status><gtr:grantCategory>Intramural</gtr:grantCategory><gtr:grantReference>MC_PC_15002</gtr:grantReference><gtr:abstractText>Abstracts are not currently available in GtR for all funded research. This is normally because the abstract was not required at the time of proposal submission, but may be because it included sensitive information such as personal details.</gtr:abstractText><gtr:technicalSummary>We will investigate whether a clinical trial of an experimental vaccine can provide a valuable source of potentially therapeutic human monoclonal antibodies to Ebola. 

We aim to isolate a cocktail of neutralizing human antibodies from vaccines to compare with the ZMapp cocktail derived from murine antibodies. ZMapp consists of 3 antibodies binding 2 sites, at the Base, and Receptor Binding Domain of the EBOV Glycoprotein.</gtr:technicalSummary><gtr:fund><gtr:end>2017-09-30</gtr:end><gtr:funder url="http://gtr.ukri.org:80/organisation/C008C651-F5B0-4859-A334-5F574AB6B57C"><gtr:id>C008C651-F5B0-4859-A334-5F574AB6B57C</gtr:id><gtr:name>MRC</gtr:name></gtr:funder><gtr:start>2015-01-01</gtr:start><gtr:type>EXPENDITURE_ACTUAL</gtr:type><gtr:valuePounds>300000</gtr:valuePounds></gtr:fund><gtr:output><gtr:artisticAndCreativeProductOutputs/><gtr:collaborationOutputs><gtr:collaborationOutput><gtr:collaboratingOrganisation>National Institute for Biological Standards and Control (NIBSC)</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:description>Collaboration with NIBSC</gtr:description><gtr:id>08E2E832-2F09-46A9-8C44-EFFBC010CA8D</gtr:id><gtr:impact>No published outcome yet</gtr:impact><gtr:outcomeId>58c7ee38973702.97215108-1</gtr:outcomeId><gtr:partnerContribution>Collaborative project</gtr:partnerContribution><gtr:piContribution>Isolation of a cocktail of neutralizing antibodies from vaccinees to compare with the ZMapp cocktail derived from murine antibodies</gtr:piContribution><gtr:sector>Public</gtr:sector><gtr:start>2016-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>EBOVAC2 Consortium</gtr:collaboratingOrganisation><gtr:country>France, French Republic</gtr:country><gtr:description>Collaboration with EBOVAC2</gtr:description><gtr:id>0094D008-6847-4E9B-AD98-2F8E6FCC6706</gtr:id><gtr:impact>No published outcome yet</gtr:impact><gtr:outcomeId>58c7ededdcb6f7.64681031-1</gtr:outcomeId><gtr:partnerContribution>Collaborative project and search through B cells of donors</gtr:partnerContribution><gtr:piContribution>Isolation of a cocktail of neutralizing antibodies from vaccinees to compare with the ZMapp cocktail derived from murine antibodies</gtr:piContribution><gtr:sector>Charity/Non Profit</gtr:sector><gtr:start>2016-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Scripps Research Institute</gtr:collaboratingOrganisation><gtr:country>United States of America</gtr:country><gtr:description>Collaboration with the Viral Hemorrhagic Fever Immunotherapeutic Consortium</gtr:description><gtr:id>D01426CC-4084-4630-8538-7AA906E2FCF8</gtr:id><gtr:impact>No published outcome yet</gtr:impact><gtr:outcomeId>58c7ec5e3a4435.00735189-1</gtr:outcomeId><gtr:partnerContribution>Collaborative project and supply of antibodies</gtr:partnerContribution><gtr:piContribution>Isolation of a cocktail of neutralizing antibodies from vaccinees to compare with the ZMapp cocktail derived from murine antibodies</gtr:piContribution><gtr:sector>Charity/Non Profit</gtr:sector><gtr:start>2016-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>HUMABs Biomed, Bellinzona,Switzerland</gtr:collaboratingOrganisation><gtr:country>Switzerland, Swiss Confederation</gtr:country><gtr:description>Collaboration with HUMABs, Switzerland</gtr:description><gtr:id>49195A5C-7E0A-41F1-8DD1-F1128E9B908C</gtr:id><gtr:impact>No published outcome yet</gtr:impact><gtr:outcomeId>58c7ed22089db2.27494506-1</gtr:outcomeId><gtr:partnerContribution>Collaborative project and supply of antibodies</gtr:partnerContribution><gtr:piContribution>Isolation of a cocktail of neutralizing antibodies from vaccinees to compare with the ZMapp cocktail derived from murine antibodies</gtr:piContribution><gtr:sector>Private</gtr:sector><gtr:start>2016-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>UCB Pharma</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:description>Collaboration with UCB Celltech</gtr:description><gtr:id>1FB09D97-2369-49C3-B9D6-D64485B34284</gtr:id><gtr:impact>No published outcome yet</gtr:impact><gtr:outcomeId>58c7ee82200c53.74695722-1</gtr:outcomeId><gtr:partnerContribution>Collaborative project</gtr:partnerContribution><gtr:piContribution>Isolation of a cocktail of neutralizing antibodies from vaccinees to compare with the ZMapp cocktail derived from murine antibodies</gtr:piContribution><gtr:sector>Private</gtr:sector><gtr:start>2016-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Public Health England</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:description>Collaboration with Public Health England</gtr:description><gtr:id>AB11A364-A919-44A6-A87D-821CBD27F5E3</gtr:id><gtr:impact>No published outcome yet</gtr:impact><gtr:outcomeId>58c7ed8647c520.45925239-1</gtr:outcomeId><gtr:partnerContribution>Collaborative project</gtr:partnerContribution><gtr:piContribution>Isolation of a cocktail of neutralizing antibodies from vaccinees to compare with the ZMapp cocktail derived from murine antibodies</gtr:piContribution><gtr:sector>Public</gtr:sector><gtr:start>2016-01-01</gtr:start></gtr:collaborationOutput></gtr:collaborationOutputs><gtr:disseminationOutputs><gtr:disseminationOutput><gtr:description>Visit by 50 students from the Utrecht Junior School, the Netherlands</gtr:description><gtr:form>Participation in an open day or visit at my research institution</gtr:form><gtr:geographicReach>International</gtr:geographicReach><gtr:id>ECAAF271-3AE1-4257-A0A3-25F4A9F39410</gtr:id><gtr:impact>A group of 50 students from Utrecht Junior College in the Netherlands took place in the WIMM and the MRC Human Immunology Unit. 100% of students who attended said that they both enjoyed the day and learnt something new about science.</gtr:impact><gtr:outcomeId>56dd826d6bbda8.15372859</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Schools</gtr:primaryAudience><gtr:year>2015</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Publication of glossy brochure for dissemination</gtr:description><gtr:form>A magazine, newsletter or online publication</gtr:form><gtr:geographicReach>National</gtr:geographicReach><gtr:id>FCD29082-12EF-4A66-9377-7C9E4798C470</gtr:id><gtr:impact>Development and publication of a glossy brochure illustrating in lay terms the important work carried out in the unit and dissemination to the general public.</gtr:impact><gtr:outcomeId>58b6adbb37e217.62815398</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Public/other audiences</gtr:primaryAudience><gtr:year>2016</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Work experience visits by 5th &amp; 6th year students</gtr:description><gtr:form>Participation in an open day or visit at my research institution</gtr:form><gtr:geographicReach>Local</gtr:geographicReach><gtr:id>7E5248F1-92F0-4FFC-A13A-F84BE38172D9</gtr:id><gtr:impact>Work experience visits to the MRC Human Immunology Unit by a total of 19 students in 2016.</gtr:impact><gtr:outcomeId>58b6aa041d0918.83906435</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Schools</gtr:primaryAudience><gtr:year>2016</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>MRC Festival of Medical Research</gtr:description><gtr:form>Participation in an activity, workshop or similar</gtr:form><gtr:geographicReach>Regional</gtr:geographicReach><gtr:id>8E9ACD43-7EDF-432F-80FA-C59986F4E5E2</gtr:id><gtr:impact>To showcase and discuss the important work carried out in the Unit</gtr:impact><gtr:outcomeId>58b6a841510588.05134194</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Public/other audiences</gtr:primaryAudience><gtr:year>2016</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Oxfordshire Science Festival</gtr:description><gtr:form>Participation in an activity, workshop or similar</gtr:form><gtr:geographicReach>Regional</gtr:geographicReach><gtr:id>EE75384A-A081-4220-8198-F18EF4ACE502</gtr:id><gtr:impact>To showcase our multi-disciplinary department through interactive demonstrations and hands-on activities.</gtr:impact><gtr:outcomeId>58b6a7b3c99473.12646672</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Public/other audiences</gtr:primaryAudience><gtr:year>2016</gtr:year></gtr:disseminationOutput></gtr:disseminationOutputs><gtr:exploitationOutputs/><gtr:furtherFundingOutputs/><gtr:impactSummaryOutputs/><gtr:intellectualPropertyOutputs/><gtr:otherResearchOutputs/><gtr:policyInfluenceOutputs/><gtr:productOutputs/><gtr:researchDatabaseAndModelOutputs/><gtr:researchMaterialOutputs/><gtr:softwareAndTechnicalProductOutputs/><gtr:spinOutOutputs/></gtr:output><gtr:publications><gtr:publication><gtr:id>3A4CEAF8-4E72-4093-87A6-E9897F0B2589</gtr:id><gtr:title>Characterization of Influenza Virus Pseudotyped with Ebolavirus Glycoprotein.</gtr:title><gtr:parentPublicationTitle>Journal of virology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/ab27b037cef373b993bcef4f67c51deb"><gtr:id>ab27b037cef373b993bcef4f67c51deb</gtr:id><gtr:otherNames>Xiao JH</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2018-01-01</gtr:date><gtr:issn>0022-538X</gtr:issn><gtr:outcomeId>5aa8df14000b22.38513283</gtr:outcomeId></gtr:publication></gtr:publications><gtr:identifiers><gtr:identifier type="RCUK">MC_PC_15002</gtr:identifier></gtr:identifiers><gtr:healthCategories><gtr:healthCategory><gtr:id>03BA7BC9-C251-48FC-8EA9-5F7414A63FEE</gtr:id><gtr:percentage>100</gtr:percentage><gtr:text>Infection</gtr:text></gtr:healthCategory></gtr:healthCategories><gtr:researchActivities><gtr:researchActivity><gtr:id>D8F3A27D-084A-40BB-A046-087DACE23410</gtr:id><gtr:percentage>100</gtr:percentage><gtr:text>3.4  Vaccines</gtr:text></gtr:researchActivity></gtr:researchActivities><gtr:researchSubjects/><gtr:researchTopics/><gtr:rcukProgrammes/></gtr:project></gtr:projectComposition></gtr:projectOverview>